237 related articles for article (PubMed ID: 29593736)
1. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a
Takeda Y; Azuma M; Funami K; Shime H; Matsumoto M; Seya T
Front Immunol; 2018; 9():496. PubMed ID: 29593736
[No Abstract] [Full Text] [Related]
2. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
3. Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2.
Sawahata R; Shime H; Yamazaki S; Inoue N; Akazawa T; Fujimoto Y; Fukase K; Matsumoto M; Seya T
Microbes Infect; 2011 Apr; 13(4):350-8. PubMed ID: 21172450
[TBL] [Abstract][Full Text] [Related]
4. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 6-independent signaling by diacylated lipopeptides.
Buwitt-Beckmann U; Heine H; Wiesmüller KH; Jung G; Brock R; Akira S; Ulmer AJ
Eur J Immunol; 2005 Jan; 35(1):282-9. PubMed ID: 15580661
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
Seya T; Takeda Y; Takashima K; Yoshida S; Azuma M; Matsumoto M
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(3):153-160. PubMed ID: 29526974
[TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
11. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
12. CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection.
Xu A; Wang R; Freywald A; Stewart K; Tikoo S; Xu J; Zheng C; Xiang J
Biochem Biophys Res Commun; 2017 Mar; 484(3):662-667. PubMed ID: 28153727
[TBL] [Abstract][Full Text] [Related]
13. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.
Takeda Y; Azuma M; Matsumoto M; Seya T
J Exp Clin Cancer Res; 2016 Sep; 35(1):143. PubMed ID: 27619885
[TBL] [Abstract][Full Text] [Related]
14. Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway.
Wang R; Xu A; Zhang X; Wu J; Freywald A; Xu J; Xiang J
Cell Mol Immunol; 2017 Jun; 14(6):529-545. PubMed ID: 27264687
[TBL] [Abstract][Full Text] [Related]
15. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
16. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
17. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
He T; Tang C; Xu S; Moyana T; Xiang J
Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
[TBL] [Abstract][Full Text] [Related]
18. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
20. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]